Peringatan Keamanan

There is new temporal evidence that perflutren may be associated with new-onset seizure activity following perflutren microbubble contrast injection during dobutamine-atropine stress echocardiography. PMID: 23432576

Perflutren

DB00556

small molecule approved

Deskripsi

Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.

Struktur Molekul 2D

Berat 188.0193
Wujud liquid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean half-life of OFP in blood 1.9 minutes
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

OFP is not metabolized. The phospholipid components of the microspheres are thought to be metabolized to free fatty acids.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

368 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of Perflutren.
Dofetilide The risk or severity of QTc prolongation can be increased when Perflutren is combined with Dofetilide.
Citalopram The risk or severity of QTc prolongation can be increased when Perflutren is combined with Citalopram.
Anagrelide The risk or severity of QTc prolongation can be increased when Perflutren is combined with Anagrelide.
Disopyramide The risk or severity of QTc prolongation can be increased when Perflutren is combined with Disopyramide.
Clemastine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Clemastine.
Ibutilide The risk or severity of QTc prolongation can be increased when Perflutren is combined with Ibutilide.
Valproic acid The risk or severity of QTc prolongation can be increased when Perflutren is combined with Valproic acid.
Terfenadine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Terfenadine.
Grepafloxacin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Grepafloxacin.
Quinine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Quinine.
Sotalol The risk or severity of QTc prolongation can be increased when Perflutren is combined with Sotalol.
Erlotinib The risk or severity of QTc prolongation can be increased when Perflutren is combined with Erlotinib.
Toremifene The risk or severity of QTc prolongation can be increased when Perflutren is combined with Toremifene.
Cisapride The risk or severity of QTc prolongation can be increased when Perflutren is combined with Cisapride.
Imatinib The risk or severity of QTc prolongation can be increased when Perflutren is combined with Imatinib.
Astemizole The risk or severity of QTc prolongation can be increased when Perflutren is combined with Astemizole.
Thioridazine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Thioridazine.
Trovafloxacin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Trovafloxacin.
Mifepristone The risk or severity of QTc prolongation can be increased when Perflutren is combined with Mifepristone.
Cocaine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Cocaine.
Quinidine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Quinidine.
Procainamide The risk or severity of QTc prolongation can be increased when Perflutren is combined with Procainamide.
Pimozide The risk or severity of QTc prolongation can be increased when Perflutren is combined with Pimozide.
Amiodarone The risk or severity of QTc prolongation can be increased when Perflutren is combined with Amiodarone.
Arsenic trioxide The risk or severity of QTc prolongation can be increased when Perflutren is combined with Arsenic trioxide.
Escitalopram The risk or severity of QTc prolongation can be increased when Perflutren is combined with Escitalopram.
Domperidone The risk or severity of QTc prolongation can be increased when Perflutren is combined with Domperidone.
Sparfloxacin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Sparfloxacin.
Halofantrine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Halofantrine.
Bepridil The risk or severity of QTc prolongation can be increased when Perflutren is combined with Bepridil.
Paliperidone The risk or severity of QTc prolongation can be increased when Perflutren is combined with Paliperidone.
Lithium cation The risk or severity of QTc prolongation can be increased when Perflutren is combined with Lithium cation.
Temafloxacin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Temafloxacin.
Zuclopenthixol The risk or severity of QTc prolongation can be increased when Perflutren is combined with Zuclopenthixol.
Tetrabenazine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Tetrabenazine.
Dronedarone The risk or severity of QTc prolongation can be increased when Perflutren is combined with Dronedarone.
Nilotinib The risk or severity of QTc prolongation can be increased when Perflutren is combined with Nilotinib.
Iloperidone The risk or severity of QTc prolongation can be increased when Perflutren is combined with Iloperidone.
Vandetanib The risk or severity of QTc prolongation can be increased when Perflutren is combined with Vandetanib.
Romidepsin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Romidepsin.
Asenapine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Asenapine.
Artemether The risk or severity of QTc prolongation can be increased when Perflutren is combined with Artemether.
Lumefantrine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Lumefantrine.
Vemurafenib The risk or severity of QTc prolongation can be increased when Perflutren is combined with Vemurafenib.
Eliglustat The risk or severity of QTc prolongation can be increased when Perflutren is combined with Eliglustat.
Ribociclib The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Perflutren.
Glasdegib The risk or severity of QTc prolongation can be increased when Perflutren is combined with Glasdegib.
Deutetrabenazine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Deutetrabenazine.
Macimorelin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Macimorelin.
Terodiline The risk or severity of QTc prolongation can be increased when Perflutren is combined with Terodiline.
Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Perflutren.
Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Perflutren.
Erythromycin The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Perflutren.
Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Perflutren.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Perflutren.
Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Perflutren.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Perflutren.
Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Perflutren.
Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with Perflutren.
Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Perflutren.
Clozapine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Clozapine.
Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Perflutren.
Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Perflutren.
Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Perflutren.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Perflutren.
Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Perflutren.
Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Perflutren.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Perflutren.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Perflutren.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Perflutren.
Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Perflutren.
Cinnarizine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Cinnarizine.
Atropine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Atropine.
Chloroquine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Chloroquine.
Efavirenz The risk or severity of QTc prolongation can be increased when Perflutren is combined with Efavirenz.
Adenosine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Adenosine.
Pentamidine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Pentamidine.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Perflutren is combined with Gadobenic acid.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Carbinoxamine.
Dolasetron The risk or severity of QTc prolongation can be increased when Perflutren is combined with Dolasetron.
Roxithromycin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Roxithromycin.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Perflutren is combined with Nalidixic acid.
Cinoxacin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Cinoxacin.
Loperamide The risk or severity of QTc prolongation can be increased when Perflutren is combined with Loperamide.
Granisetron The risk or severity of QTc prolongation can be increased when Perflutren is combined with Granisetron.
Ondansetron The risk or severity of QTc prolongation can be increased when Perflutren is combined with Ondansetron.
Levosimendan The risk or severity of QTc prolongation can be increased when Perflutren is combined with Levosimendan.
Mesoridazine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Mesoridazine.
Desloratadine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Desloratadine.
Telithromycin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Telithromycin.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Lomefloxacin.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Perflutren is combined with Dimenhydrinate.
Primaquine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Primaquine.
Papaverine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Papaverine.
Chlorpheniramine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Chlorpheniramine.
Nifedipine The risk or severity of QTc prolongation can be increased when Perflutren is combined with Nifedipine.
Levofloxacin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Levofloxacin.
Gemifloxacin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Gemifloxacin.
Ofloxacin The risk or severity of QTc prolongation can be increased when Perflutren is combined with Ofloxacin.

Referensi & Sumber

Synthesis reference: James L. Webster, Steven H. Swearingen, Douglas W. Bruhnke, Leo E. Manzer, Elrey L. McCann, "Synthesis of perfluoropropane." U.S. Patent US5220083, issued August, 1967.
Artikel (PubMed)
  • PMID: 23432576
    Quinones A, Benenstein R, Saric M: New-onset seizure after perflutren microbubble injection during dobutamine stress echocardiography. Echocardiography. 2013 Apr;30(4):E95-7. doi: 10.1111/echo.12149. Epub 2013 Feb 22.

Contoh Produk & Brand

Produk: 8 • International brands: 1
Produk
  • Definity
    Injection, suspension • 6.52 mg/1mL • Intravenous • US • Approved
  • Definity
    Suspension • 150 mcL / mL • Intravenous • Canada • Approved
  • Definity RT
    Injection, suspension • 6.52 mg/1mL • Intravenous • US • Approved
  • Luminity
    Injection, solution • 150 μl/ml • Intravenous • EU • Approved
  • Luminity
    Injection, solution • 150 μl/ml • Intravenous • EU • Approved
  • Optison
    - • 0.19 mg/ml • Intravenous • EU • Approved
  • Optison
    - • 0.19 mg/ml • Intravenous • EU • Approved
  • Optison Perflutren Protein-Type A Microspheres
    Injection, solution • - • Intravenous • US • Approved
International Brands
  • Optison

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul